(Q42439772)

31 October 2017

0 references

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy (English)

1 reference

31 October 2017

1 reference

Stefan Glück

1

1 reference

31 October 2017

Femke de Snoo

2

1 reference

31 October 2017

Justine Peeters

3

1 reference

31 October 2017

Lisette Stork-Sloots

4

1 reference

31 October 2017

George Somlo

5

1 reference

31 October 2017

language of work or name

English

0 references

publication date

12 June 2013

1 reference

Breast Cancer Research and Treatment

31 October 2017

1 reference

31 October 2017

139

1 reference

31 October 2017

3

1 reference

31 October 2017

759-767

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2572-4

31 October 2017

0 references

cites work

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Neoadjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Neoadjuvant chemotherapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Advocates' perspective: neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Practical implications of gene-expression-based assays for breast oncologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2572-4

10.1007/S10549-013-2572-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 October 2017

0 references

1 reference